Nile Therapeutics, Inc. Share Price Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
17/05 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
13/05 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Sales 2024 * | 2.66Cr 221.34Cr | Sales 2025 * | 7.86Cr 654.71Cr | Capitalization | 19Cr 1.61TCr |
---|---|---|---|---|---|
Net income 2024 * | -3.3Cr -274.83Cr | Net income 2025 * | -40L -33Cr | EV / Sales 2024 * | 7.25 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
-5.89
x | P/E ratio 2025 * |
-26.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20/13/20 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20/13/20 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21/23/21 |
Earl Collier
BRD | Director/Board Member | 76 | 20/13/20 |
George Dunbar
BRD | Director/Board Member | 77 | 20/13/20 |
1st Jan change | Capi. | |
---|---|---|
+9.83% | 12TCr | |
+10.80% | 10TCr | |
-10.84% | 2.27TCr | |
-0.67% | 2.18TCr | |
-10.88% | 1.82TCr | |
-41.92% | 1.65TCr | |
-15.11% | 1.6TCr | |
+6.62% | 1.41TCr | |
+17.53% | 1.07TCr |